Chronic Bronchitis - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Chronic Bronchitis - Pipeline Review, H2 2015’, provides an overview of the Chronic Bronchitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Bronchitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Bronchitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Bronchitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Bronchitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Bronchitis Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Bronchitis - Overview 7
Pipeline Products for Chronic Bronchitis - Comparative Analysis 8
Chronic Bronchitis - Therapeutics under Development by Companies 9
Chronic Bronchitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Chronic Bronchitis - Products under Development by Companies 13
Chronic Bronchitis - Companies Involved in Therapeutics Development 14
Boehringer Ingelheim GmbH 14
Hyundai Pharmaceutical Co., Ltd. 15
Invion Limited 16
Nippon Shinyaku Co., Ltd. 17
Chronic Bronchitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
BI-113608 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
HOB-051 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
nadolol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
prulifloxacin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TRN-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Chronic Bronchitis - Recent Pipeline Updates 33
Chronic Bronchitis - Dormant Projects 36
Chronic Bronchitis - Discontinued Products 37
Chronic Bronchitis - Product Development Milestones 38
Featured News & Press Releases 38
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 38
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40
List Of Tables
Number of Products under Development for Chronic Bronchitis, H2 2015 7
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Chronic Bronchitis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 14
Chronic Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 15
Chronic Bronchitis - Pipeline by Invion Limited, H2 2015 16
Chronic Bronchitis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 17
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 25
Chronic Bronchitis Therapeutics - Recent Pipeline Updates, H2 2015 33
Chronic Bronchitis - Dormant Projects, H2 2015 36
Chronic Bronchitis - Discontinued Products, H2 2015 37
List Of Figures
Number of Products under Development for Chronic Bronchitis, H2 2015 7
Number of Products under Development for Chronic Bronchitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Top 10 Targets, H2 2015 19
Number of Products by Stage and Top 10 Targets, H2 2015 19
Number of Products by Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Top 10 Routes of Administration, H2 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23
Number of Products by Stage and Top 10 Molecule Types, H2 2015 25
